Added to YB: 2026-04-17
Pitch date: 2026-04-16
DBVT [bearish]
DBV Technologies S.A.
Author Info
Molecule -> Market is a financial analyst specializing in pharmaceutical and biotechnology companies. I publish detailed research on biotech stocks, using DCF modeling, clinical trial analysis, and market positioning data. Sign up for the newsletter.
Company Info
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
Market Cap
EUR 1.3B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-8.12
P/E
-4.32
EV/Sales
205.53
Sector
Biotechnology
Category
special_situation
DBV Technologies: Asymmetric Downside
DBVT (short): Viaskin peanut patch targets shrinking market (peanut allergy incidence down 43% since 2017 per CHOP data). VITESSE showed 46.6% response vs 67% for Palforzia (which failed commercially, sold for pennies). Patch requires 20hr/day wear, protects against ~1 peanut, no sustained unresponsiveness data. Faces Xolair competition (multi-allergen coverage), biosimilars launching. No commercial infrastructure, $288M cash vs $121M/yr burn, runway only to Q2'27. CRL risk high on adhesion issues. Core patents expire 2028-2031. Even if approved, launch likely fails—asymmetric downside >80%.
Read full article (8 min)